Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 19;24(1):108.
doi: 10.1186/s12885-024-11858-x.

The role of molecular tumor boards in neuro-oncology: a nationwide survey

Lisa S Hönikl  1   2 , Sebastian Lange  3   4 , Vicki M Butenschoen  5 , Claire Delbridge  3   6 , Bernhard Meyer  5 , Stephanie E Combs  7 , Anna Lena Illert  3   8 , Friederike Schmidt-Graf  3   9
Affiliations

The role of molecular tumor boards in neuro-oncology: a nationwide survey

Lisa S Hönikl et al. BMC Cancer. .

Abstract

Background: In neuro-oncology, the inclusion of tumor patients in the molecular tumor board has only become increasingly widespread in recent years, but so far there are no standards for indication, procedure, evaluation, therapy recommendations and therapy implementation of neuro-oncological patients. The present work examines the current handling of neuro-oncological patients included in molecular tumor boards in Germany.

Methods: We created an online based survey with questions covering the handling of neuro-oncologic patient inclusion, annotation of genetic analyses, management of target therapies and the general role of molecular tumor boards in neuro-oncology in Germany. We contacted all members of the Neuro-Oncology working group (NOA) of the German Cancer Society (DKG) by e-mail.

Results: 38 responses were collected. The majority of those who responded were specialists in neurosurgery or neurology with more than 10 years of professional experience working at a university hospital. Molecular tumor boards (MTB) regularly take place once a week and all treatment disciplines of neuro-oncology patients take part. The inclusions to the MTB are according to distinct tumors and predominantly in case of tumor recurrence. An independently MTB member mostly create the recommendations, which are regularly implemented in the tumor treatment. Recommendations are given for alteration classes 4 and 5. Problems exist mostly within the cost takeover of experimental therapies. The experimental therapies are mostly given in the department of medical oncology.

Conclusions: Molecular tumor boards for neuro-oncological patients, by now, are not standardized in Germany. Similarities exists for patient inclusion and interpretation of molecular alterations; the time point of inclusion and implementation during the patient treatment differ between the various hospitals. Further studies for standardization and harmonisation are needed. In summary, most of the interviewees envision great opportunities and possibilities for molecular-based neuro-oncological therapy in the future.

Keywords: MTB; Molecular tumor board; Neuro-oncology; Personalized medicine; Precision oncology; Target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Composition of the participating cohort. Responders were mostly neurosurgeons or neurologists (A) in supervising positions (B) with more than 10 years of professional experience (C) and working in University hospitals or University teaching hospitals (D)
Fig. 2
Fig. 2
Overview of inclusion criteria for the MTB
See this image and copyright information in PMC

References

    1. Snyder J, Schultz L, Walbert T. The role of tumor board conferences in neuro-oncology: a nationwide provider survey. J Neurooncol. 2017;133(1):1–7. doi: 10.1007/s11060-017-2416-x. - DOI - PubMed
    1. Louis DN, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Wick W, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019;21(1):95–105. doi: 10.1093/neuonc/noy161. - DOI - PMC - PubMed
    1. Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–86. doi: 10.1038/s41571-020-00447-z. - DOI - PMC - PubMed
    1. Luchini C, et al. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6(9):738–44. doi: 10.1016/j.trecan.2020.05.008. - DOI - PubMed